Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

References

• Gabler K, Behrmann I, Haan C. JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT. 2013;2:e25025.
   PubMedGoogle Scholar
• Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res. 2016;5:700.
   Google Scholar
• Cancer Network. Myeloproliferative Neoplasms; 2016 [2017 Feb 7]. Available from: http://www.cancernetwork.com/cancer-management/myeloproliferative-neoplasms/page/0/1.
   Google Scholar
• Mehra M, Potluri R, He J, et al. Characterization of disease, treatment patterns, and outcomes of patients with myelofibrosis: analysis of 2 United States commercial claims databases. Am Soc Hematology. 2016;128(22):4769.
   Google Scholar
• Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600.
   PubMed Web of Science ®Google Scholar
• Masarova L, Bose P, Daver N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110–116.
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788–22792.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061.
   PubMed Web of Science ®Google Scholar
• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Incyte Corporation. Highlights of prescribing information; 2011 [2018 Aug 12]. Available from: https://www.jakafi.com/pdf/prescribing-information.pdf.
   Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4(12):e268–e268.
   PubMedGoogle Scholar
• Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435–441.
   PubMed Web of Science ®Google Scholar
• Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130(9):1125–1131.
   PubMed Web of Science ®Google Scholar
• Spiegel JY, McNamara C, Kennedy JA, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv. 2017;1(20):1729–1738.
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV3–IV18.
   Web of Science ®Google Scholar
• Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol. 2008;1(3):391–400.
   PubMedGoogle Scholar
• He J, Mehra M, Bussolari J, et al., editors. Characterization of disease and outcomes of patients with myelofibrosis: A population based study. Haematologica. Pavia, Italy: Ferrata Storti Foundation; 2017.
   Google Scholar
• Fonseca E, Silver RT, Kazis LE, et al. Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice. Blood. 2013;122(21):2833–2833.
   Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053.
   PubMed Web of Science ®Google Scholar
• Davis KL, Cote I, Kaye JA, et al. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015;2015:1–9.
   Google Scholar
• Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012;119(12):2721–2730.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13–21.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
   PubMed Web of Science ®Google Scholar
• Cubanski J, Senate U. An overview of the medicare program and medicare beneficiaries’costs and service use; 2013 [2018 Aug 12]. Available from: https://kaiserfamilyfoundation.files.wordpress.com/2013/02/an-overview-of-the-medicare-program-and-medicare-beneficiaries-costs-and-service-use-testimony.pdf.
   Google Scholar
• Howlader N, Ries LA, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584–1598.
   PubMedGoogle Scholar